UNLABELLED: The HIV-1 envelope protein (Env) is heavily glycosylated, with approximately 50% of the Env molecular mass being contributed by N-glycans. HIV-1 Env N-glycans shield the protein backbone and have been shown to play key roles in determining Env structure, surface exposure, and, consequently, antigenicity, infectivity, antibody neutralization, and carbohydrate and receptor binding. Studies of HIV-1 glycosylation have focused mainly on the position of glycosylation, rather than the types of glycans. Also, the role of Env glycan moieties on HIV-1 transmission has not been systematically defined. Using viruses with modified Env glycan content and heterogeneity, we examined the effects of Env glycan moieties on the major events of HIV-1 transmission. Compared to viruses with less oligomannose and more complex Env glycans, viruses with more oligomannose and less complex glycans more efficiently (i) transcytosed across an epithelial cell monolayer, (ii) attached to monocyte-derived macrophages (MDMs), (iii) bound monocyte-derived dendritic cells (MoDCs), and (iv) trans-infected primary lymphocytes via MoDCs. However, viruses with more oligomannose and less complex glycans displayed impaired infectivity in TZMbl cells, MDMs, primary lymphocytes, and fresh human intestinal tissue. Thus, N-linked Env glycans display discordant effects on the major events of HIV-1 transmission, with mature oligosaccharide structures on Env playing a crucial role in HIV-1 infection. Env glycosylation should be taken into consideration in the development of vaccine strategies to interdict HIV-1 transmission. IMPORTANCE: HIV-1 Env N-glycans shield the protein backbone and play key roles in determining Env structure and surface exposure, thereby impacting Env antigenicity, infectivity, antibody neutralization, and carbohydrate and receptor binding. Studies of HIV-1 glycosylation have focused mainly on the position of glycosylation, rather than the types of glycans. In the study described in this report, we investigated systematically the role of Env glycan moieties on HIV-1 transmission. We show that N-linked Env glycans display discordant effects on the major events of HIV-1 transmission. These data indicate that Env glycan moieties impact HIV-1 transmission and that modulation of Env glycan moieties offers a potential strategy for the development of therapeutic or prophylactic vaccines against HIV-1.

Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA

Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA VA Medical Center Birmingham Alabama USA

Department of Microbiology University of Alabama at Birmingham Birmingham Alabama USA

Department of Microbiology University of Alabama at Birmingham Birmingham Alabama USA Department of Immunology Palacky University in Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. 1992. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358–361. 10.1038/360358a0. PubMed DOI

Fennie C, Lasky LA. 1989. Model for intracellular folding of the human immunodeficiency virus type 1 gp120. J. Virol. 63:639–646. PubMed PMC

Moulard M, Decroly E. 2000. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim. Biophys. Acta 1469:121–132. 10.1016/S0304-4157(00)00014-9. PubMed DOI

Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, Sutherland LL, Alam SM, Haynes BF, Desaire H. 2008. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J. Proteome Res. 7:1660–1674. 10.1021/pr7006957. PubMed DOI PMC

Zhu X, Borchers C, Bienstock RJ, Tomer KB. 2000. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39:11194–11204. 10.1021/bi000432m. PubMed DOI

Geyer H, Holschbach C, Hunsmann G, Schneider J. 1988. Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J. Biol. Chem. 263:11760–11767. PubMed

Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648–659. 10.1038/31405. PubMed DOI PMC

Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019–2022. 10.1126/science.1093137. PubMed DOI

Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307–312. 10.1038/nature01470. PubMed DOI

Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552–7557. 10.1073/pnas.0802203105. PubMed DOI PMC

Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM, Shaw GM, Hahn BH. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82:3952–3970. 10.1128/JVI.02660-07. PubMed DOI PMC

Quinones-Kochs MI, Buonocore L, Rose JK. 2002. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 76:4199–4211. 10.1128/JVI.76.9.4199-4211.2002. PubMed DOI PMC

Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW. 2010. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 84:5637–5655. 10.1128/JVI.00105-10. PubMed DOI PMC

Montefiori DC, Robinson WE, Jr, Mitchell WM. 1988. Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 85:9248–9252. 10.1073/pnas.85.23.9248. PubMed DOI PMC

Wolk T, Schreiber M. 2006. N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195:165–172. 10.1007/s00430-006-0016-z. PubMed DOI

Huang X, Jin W, Hu K, Luo S, Du T, Griffin GE, Shattock RJ, Hu Q. 2012. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423:97–106. 10.1016/j.virol.2011.11.023. PubMed DOI

Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, Chen XS, Wang Y. 2013. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10:14. 10.1186/1742-4690-10-14. PubMed DOI PMC

Francois KO, Balzarini J. 2011. The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J. Biol. Chem. 286:42900–42910. 10.1074/jbc.M111.274456. PubMed DOI PMC

Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, Cheng-Mayer C. 2000. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J. Virol. 74:11008–11016. 10.1128/JVI.74.23.11008-11016.2000. PubMed DOI PMC

Yen PJ, Herschhorn A, Haim H, Salas I, Gu C, Sodroski J, Gabuzda D. 2014. Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. J. Virol. 88:5014–5028. 10.1128/JVI.02785-13. PubMed DOI PMC

Kornfeld R, Kornfeld S. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631–664. 10.1146/annurev.bi.54.070185.003215. PubMed DOI

Crispin MD, Ritchie GE, Critchley AJ, Morgan BP, Wilson IA, Dwek RA, Sim RB, Rudd PM. 2004. Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Lett. 566:270–274. 10.1016/j.febslet.2004.04.045. PubMed DOI

Scanlan CN, Offer J, Zitzmann N, Dwek RA. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446:1038–1045. 10.1038/nature05818. PubMed DOI

Iacob RE, Perdivara I, Przybylski M, Tomer KB. 2008. Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J. Am. Soc. Mass. Spectrom. 19:428–444. 10.1016/j.jasms.2007.11.022. PubMed DOI PMC

Hanisch FG, Breloy I. 2009. Protein-specific glycosylation: signal patches and cis-controlling peptidic elements. Biol. Chem. 390:619–626. 10.1515/BC.2009.043. PubMed DOI

Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U. S. A. 107:13800–13805. 10.1073/pnas.1006498107. PubMed DOI PMC

Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, Burton DR, Crispin M, Scanlan CN. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6:e23521. 10.1371/journal.pone.0023521. PubMed DOI PMC

Auwerx J, Francois KO, Covens K, Van Laethem K, Balzarini J. 2008. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 382:10–19. 10.1016/j.virol.2008.09.010. PubMed DOI

Sadat MA, Moir S, Chun TW, Lusso P, Kaplan G, Wolfe L, Memoli MJ, He M, Vega H, Kim LJ, Huang Y, Hussein N, Nievas E, Mitchell R, Garofalo M, Louie A, Ireland DC, Grunes C, Cimbro R, Patel V, Holzapfel G, Salahuddin D, Bristol T, Adams D, Marciano BE, Hegde M, Li Y, Calvo KR, Stoddard J, Justement JS, Jacques J, Long Priel DA, Murray D, Sun P, Kuhns DB, Boerkoel CF, Chiorini JA, Di Pasquale G, Verthelyi D, Rosenzweig SD. 2014. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N. Engl. J. Med. 370:1615–1625. 10.1056/NEJMoa1302846. PubMed DOI PMC

Shen R, Kappes JC, Smythies LE, Richter HE, Novak L, Smith PD. 2014. Vaginal myeloid dendritic cells transmit founder HIV-1. J. Virol. 88:7683–7688. 10.1128/JVI.00766-14. PubMed DOI PMC

Hladik F, McElrath MJ. 2008. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8:447–457. 10.1038/nri2302. PubMed DOI PMC

Shen R, Richter HE, Smith PD. 2011. Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am. J. Reprod. Immunol. 65:261–267. 10.1111/j.1600-0897.2010.00939.x. PubMed DOI PMC

Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65:3973–3985. PubMed PMC

Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S, Dandekar S, Clapham PR, Smythies LE, Smith PD. 2009. Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J. Virol. 83:3258–3267. 10.1128/JVI.01796-08. PubMed DOI PMC

Shen R, Drelichman ER, Bimczok D, Ochsenbauer C, Kappes JC, Cannon JA, Tudor D, Bomsel M, Smythies LE, Smith PD. 2010. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J. Immunol. 184:3648–3655. 10.4049/jimmunol.0903346. PubMed DOI PMC

Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, Moldoveanu Z, Elliott MC, Wilson L, Brown R, Jancova D, Barnes S, Vrbkova J, Tomana M, Smith PD, Mestecky J, Renfrow MB, Novak J. 2010. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J. Biol. Chem. 285:20860–20869. 10.1074/jbc.M109.085472. PubMed DOI PMC

Shen R, Meng G, Ochsenbauer C, Clapham PR, Grams J, Novak L, Kappes JC, Smythies LE, Smith PD. 2011. Stromal down-regulation of macrophage CD4/CCR5 expression and NF-kappaB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog. 7:e1002060. 10.1371/journal.ppat.1002060. PubMed DOI PMC

Shen R, Smythies LE, Clements RH, Novak L, Smith PD. 2010. Dendritic cells transmit HIV-1 through human small intestinal mucosa. J. Leukoc. Biol. 87:663–670. 10.1189/jlb.0909605. PubMed DOI PMC

Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896–1905. 10.1128/AAC.46.6.1896-1905.2002. PubMed DOI PMC

Shen R, Smith PD. 2014. Mucosal correlates of protection in HIV-1-exposed sero-negative persons. Am. J. Reprod. Immunol. 72:219–227. 10.1111/aji.12202. PubMed DOI PMC

Bomsel M, Alfsen A. 2003. Entry of viruses through the epithelial barrier: pathogenic trickery. Nat. Rev. Mol. Cell Biol. 4:57–68. 10.1038/nrm1005. PubMed DOI PMC

Shen R, Richter HE, Smith PD. 2014. Interactions between HIV-1 and mucosal cells in the female reproductive tract. Am. J. Reprod. Immunol. 71:608–617. 10.1111/aji.12244. PubMed DOI PMC

van Montfort T, Eggink D, Boot M, Tuen M, Hioe CE, Berkhout B, Sanders RW. 2011. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J. Immunol. 187:4676–4685. 10.4049/jimmunol.1101876. PubMed DOI PMC

Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW. 2010. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401:236–247. 10.1016/j.virol.2010.02.019. PubMed DOI PMC

Kuo TT, de Muinck EJ, Claypool SM, Yoshida M, Nagaishi T, Aveson VG, Lencer WI, Blumberg RS. 2009. N-Glycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. J. Biol. Chem. 284:8292–8300. 10.1074/jbc.M805877200. PubMed DOI PMC

Fearon DT, Locksley RM. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50–53. 10.1126/science.272.5258.50. PubMed DOI

Stahl PD, Ezekowitz RA. 1998. The mannose receptor is a pattern recognition receptor involved in host defense. Curr. Opin. Immunol. 10:50–55. 10.1016/S0952-7915(98)80031-9. PubMed DOI

Takahashi K, Donovan MJ, Rogers RA, Ezekowitz RA. 1998. Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res. 292:311–323. 10.1007/s004410051062. PubMed DOI

Nguyen DG, Hildreth JE. 2003. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 33:483–493. 10.1002/immu.200310024. PubMed DOI

Trujillo JR, Rogers R, Molina RM, Dangond F, McLane MF, Essex M, Brain JD. 2007. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc. Natl. Acad. Sci. U. S. A. 104:5097–5102. 10.1073/pnas.0611263104. PubMed DOI PMC

Volker C, De Praeter CM, Hardt B, Breuer W, Kalz-Fuller B, Van Coster RN, Bause E. 2002. Processing of N-linked carbohydrate chains in a patient with glucosidase I deficiency (CDG type IIb). Glycobiology 12:473–483. 10.1093/glycob/cwf050. PubMed DOI

De Praeter CM, Gerwig GJ, Bause E, Nuytinck LK, Vliegenthart JF, Breuer W, Kamerling JP, Espeel MF, Martin JJ, De Paepe AM, Chan NW, Dacremont GA, Van Coster RN. 2000. A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency. Am. J. Hum. Genet. 66:1744–1756. 10.1086/302948. PubMed DOI PMC

Piguet V, Steinman RM. 2007. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28:503–510. 10.1016/j.it.2007.07.010. PubMed DOI PMC

Wu L, KewalRamani VN. 2006. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6:859–868. 10.1038/nri1960. PubMed DOI PMC

Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ. 2007. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26:257–270. 10.1016/j.immuni.2007.01.007. PubMed DOI PMC

Gurney KB, Elliott J, Nassanian H, Song C, Soilleux E, McGowan I, Anton PA, Lee B. 2005. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J. Virol. 79:5762–5773. 10.1128/JVI.79.9.5762-5773.2005. PubMed DOI PMC

Feinberg H, Mitchell DA, Drickamer K, Weis WI. 2001. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294:2163–2166. 10.1126/science.1066371. PubMed DOI

Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie JA, Doms RW. 2003. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77:1337–1346. 10.1128/JVI.77.2.1337-1346.2003. PubMed DOI PMC

Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. 2003. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J. Leukoc. Biol. 74:710–718. 10.1189/jlb.0503208. PubMed DOI

Geijtenbeek TBH, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GCF, Middel J, Cornelissen ILMHA, Nottet HSLM, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587–597. 10.1016/S0092-8674(00)80694-7. PubMed DOI

Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. 2002. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16:135–144. 10.1016/S1074-7613(02)00259-5. PubMed DOI

McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. 2003. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300:1295–1297. 10.1126/science.1084238. PubMed DOI

de Witte L, Nabatov A, Geijtenbeek TB. 2008. Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol. Med. 14:12–19. 10.1016/j.molmed.2007.11.001. PubMed DOI

de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V, van Kooyk Y, Geijtenbeek TB. 2007. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13:367–371. 10.1038/nm1541. PubMed DOI

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies